trending Market Intelligence /marketintelligence/en/news-insights/trending/Qcd7omv-wyRO4IcAT_idgQ2 content esgSubNav
In This List

Novartis Oncology CEO to retire

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Novartis Oncology CEO to retire

Novartis AG said Novartis Oncology CEO Bruno Strigini will retire for personal reasons.

He will step back from Novartis' executive committee by Dec. 31 and fully hand over in early 2018, the company said in a news release.

Strigini joined Novartis in 2014 as president of oncology and became CEO of the unit in July 2016. He previously served as Merck & Co. Inc.'s president for Europe and Canada.